Niagen Bioscience, Inc. (NAGE)

NASDAQ: NAGE · USD

$2.54

+0.04 (+1.6%)· Recorded snapshot

Market cap	201.4M
Revenue (ttm)	129.1M
Net income (ttm)	16M
EPS (ttm)	$0.19
Shares out	79.3M
P/E (trailing)	13.4x
P/E (forward)	38.1x
Volume	297,031
Beta	2.02

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 129.1M
Net income (ttm): 16M
EPS (ttm): $0.19
P/E (trailing): 13.4x
P/E (forward): 38.1x
Market cap: 201.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ADM	Archer-Daniels-Midland Company	37.3B	21.2x	0.5x	5.0%	+1.8%	+28.5%	Ridurre
BF.B	Brown-Forman Corporation Class B	12.7B	17.9x	3.3x	14.3%	+1.6%	+0.4%	Comprare
CAG	Conagra Brands, Inc.	6.6B	—	0.6x	9.2%	+0.2%	-18.9%	Acquisto forte

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E38.1

P25 n/aP50 n/aP75 n/a

Trailing P/E13.4

P25 n/aP50 n/aP75 n/a

ROE21.8

P25 n/aP50 n/aP75 n/a

ROIC44

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NAGE indicators

Market & fundamental data

Available fields

251

Groups with data

Currency

USD

Showing 251 of 251 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001386570
Company name	Niagen Bioscience, Inc.
Country	United States
Country code	US
CUSIP number	171077407
Earnings date	2026-11-04
Earnings time	amc
Employees	117
Employees change	13
Employees growth	12.5%
Enterprise value	$137.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
In index	RUSSELL2000
Industry	Packaged Foods
Is primary listing	Yes
Is SPAC	No
ISIN number	US1710774076
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2016-04-13
Last stock split type	Reverse
Market cap	$201.4M
Market cap category	Micro-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$2.54
Price currency	USD
Sector	Consumer Staples
Stock price date	2026-10-28
Symbol	NAGE
U.S. state	California
Website	https://www.niagenbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	22.39x
Average P/E ratio (3Y)	54.69x
Earnings yield	7.49%
EV/Earnings	8.48x
EV/EBIT	15.74x
EV/EBITDA	14.13x
EV/FCF	23.89x
EV/Sales	1.05x
FCF / EV yield	4.19%
FCF yield	2.84%
Forward EV/Sales	0.95x
Forward P/E	38.12x
Forward P/S	1.4x
Graham number	2.11309
Graham upside	-16.15%
Industry forward P/E	12.41x
Industry P/E	68.48x
P/B ratio	2.4x
P/E ratio	13.36x
P/FCF ratio	35.22x
P/OCF ratio	33.59x
P/S ratio	1.55x
Price / tangible book value	2.59x
Price/EBITDA ratio	20.83x
Sector forward P/E	21.33x
Sector P/E	28.29x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	6.67%
EBITDA margin	7.43%
Effective tax rate	6.09%
FCF margin	4.4%
Gross margin	64.24%
Operating margin	6.67%
Pretax margin	13.19%
Profit margin	12.39%
Profit per employee	$136,675
Profitable quarters	8
Profitable years	2
Revenue per employee	$1.1M
ROA	5.44%
ROA (5Y)	-8.87%
ROCE	9.41%
ROE	21.8%
ROE (5Y)	-26.69%
ROIC	44%
ROIC (5Y)	-94.24%
SBC / revenue	5.38%
Tax / revenue	0.8%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-11.65%
EPS growth (Q)	-75%
EPS growth (QoQ)	-85.71%
EPS growth years	4
FCF growth	-72.9%
FCF growth (Q)	140.63%
FCF growth 3Y	50.07%
Gross profit growth	12.07%
Gross profit growth (Q)	-4.51%
Gross profit growth 3Y	19.91%
Gross profit growth 5Y	16.94%
Net income growth	-9.8%
Net income growth (Q)	-73.32%
Net income growth (QoQ)	-84.76%
Net income growth years	4
OCF growth	-71.95%
OCF growth (Q)	121.76%
OCF growth 3Y	43.72%
Operating income growth	-48.32%
Operating income growth (Q)	-78.02%
Revenue growth	10.99%
Revenue growth (Q)	-4.28%
Revenue growth (QoQ)	-5.37%
Revenue growth 10Y	18.36%
Revenue growth 3Y	16.84%
Revenue growth 5Y	15.79%
Revenue growth years	8

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-275,000
Depreciation and amortization	$976,000
EBIT	$8.6M
EBITDA	$9.6M
EPS	$0.19
FCF per share	$0.07
Financing cash flow	$-4.7M
Free cash flow	$5.7M
Free cash flow minus SBC	$-1.3M
Gross profit	$82.9M
Income taxes	$1M
Investing cash flow	$5M
Net borrowing	$-6,000
Net cash flow	$6.3M
Net income	$16M
Operating cash flow minus SBC	$-994,000
Operating income	$8.6M
Revenue	$129.1M
Stock-based compensation	$6.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	13.6
Book value per share	$1.04
Debt / EBITDA	0.21
Debt / equity	0.03
Debt / FCF	0.41
Long-term assets	$8.8M
Long-term liabilities	$9M
Net cash (debt)	$64.3M
Net cash / market cap	32.16%
Net cash growth	12.68%
Net debt / EBITDA	-6.7
Net debt / equity	-0.78
Net debt / FCF	-11.33
Piotroski F-Score	5
Property, plant and equipment	$3.1M
Shareholders' equity	$82.5M
Tangible book value	$77.2M
Tangible book value per share	$0.98
Total assets	$106.6M
Total cash	$66.6M
Total debt	$2.3M
Total liabilities	$24.1M
WACC	15.17%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.3
Current assets	$97.8M
Current liabilities	$15.1M
Current ratio	6.5
Inventory turnover	2.63
Net working capital	$17.1M
Quick ratio	4.99
Working capital	$82.7M
Working capital turnover	1.76

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.25%
Dividend yield	0%
Shareholder yield	-2.25%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-9.43%
10Y return CAGR	-0.99%
10Y total return	-9.43%
150-day SMA	$3.50
15Y price change	0.99%
15Y return CAGR	0.07%
15Y total return	0.99%
1D price change	1.6%
1M price change	-16.56%
1M total return	-16.56%
1W price change	1.39%
1W total return	1.39%
1Y price change	-66.51%
1Y return CAGR	-66.54%
1Y total return	-66.51%
20-day SMA	$2.58
200-day SMA	$3.96
3M price change	-21.21%
3M total return	-21.21%
3Y price change	92.8%
3Y return CAGR	24.46%
3Y total return	92.8%
50-day SMA	$2.89
50-day SMA vs 200-day SMA	50under200
52-week high	$7.95
52-week high date	2025-11-05
52-week low	$2.39
52-week low date	2026-10-26
5Y price change	-58.48%
5Y return CAGR	-16.12%
5Y total return	-58.48%
6M price change	-48.69%
6M total return	-48.69%
All-time high	$23.66
All-time high date	2021-02-25
All-time low	$0.33
All-time low date	2009-08-03
Average true range (ATR)	$0.09
Average volume	592.1K
Beta (1Y)	0.98
Beta (2Y)	0.79
Beta (5Y)	2.02
Change from 52-week high	-68.05%
Change from 52-week low	6.5%
Change from all-time high	-89.24%
Change from all-time low	671.21%
Change from open	2.42%
Day's gap	-0.8%
Dollar volume	$754,459
High price	$2.55
Low price	$2.48
Monthly RSI	38.7
Open price	$2.48
Position in 52-week range	92.31%
Premarket change	0.58%
Premarket close	$2.50
Premarket price	$2.51
Premarket volume	691
Previous close	$2.50
Price vs 150-day SMA	-27.26%
Price vs 20-day SMA	-1.43%
Price vs 200-day SMA	-35.68%
Price vs 50-day SMA	-11.91%
Relative volume	0.5
RSI	40.99
Sharpe ratio	-2.19
Sharpe ratio (3Y)	0.59
Sharpe ratio (5Y)	0.06
Sortino ratio	-2.52
Sortino ratio (3Y)	1.19
Sortino ratio (5Y)	0.19
Volume	297K
Weekly RSI	28.18
YTD price change	-59.98%
YTD total return	-59.98%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	59.1M
Float percentage	74.5%
Shares change (QoQ)	-2.44%
Shares change (YoY)	2.25%
Shares held by insiders	25.02%
Shares held by institutions	45.23%
Shares outstanding	79.3M
Short % of float	6.56%
Short % of shares	4.89%
Short ratio	10.1 days

Deeper analysis on NAGE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NAGE report

Is a complete NAGE research report available?

No complete published report is available for Niagen Bioscience, Inc. (NAGE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Niagen Bioscience, Inc. (NAGE)

Price

Financial snapshot

Fair-value bridge

Latest news · NAGE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NAGE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NAGE

Frequently asked questions